A Phase 1 Study of the Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in Subjects With Recurrent Mature B-Cell Neoplasms
Phase of Trial: Phase I
Latest Information Update: 23 Mar 2017
At a glance
- Drugs Ibrutinib (Primary)
- Indications Chronic lymphocytic leukaemia; Follicular lymphoma; Mantle-cell lymphoma
- Focus Adverse reactions
- Sponsors Janssen Pharmaceutical KK
- 20 Mar 2017 Status changed from active, no longer recruiting to completed.
- 02 Oct 2015 Planned End Date changed from 1 Aug 2015 to 1 Dec 2016 as reported by ClinicalTrials.gov record.
- 02 Oct 2015 Planned primary completion date changed from 1 Aug 2015 to 1 Dec 2016 as reported by ClinicalTrials.gov record.